Entresto, also known as LCZ696, is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot pump blood efficiently. Analysts estimate it could have annual sales of some $4.4 billion by 2020. Basel-based Novartis said it is waiting for final approval from the European Commission before setting a price for the drug.
Novartis" new heart drug on track for approval in Europe
Friday, 25 September 2015
Novartis" new heart drug on track for approval in Europe
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment